Vistagen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Market Cap: US$125.9m

Vistagen Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Vistagen Therapeutics has a total shareholder equity of $123.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $131.1M and $7.8M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$126.56m
EquityUS$123.28m
Total liabilitiesUS$7.78m
Total assetsUS$131.07m

Recent financial health updates

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Recent updates

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10
Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07
VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

VistaGen initiates late-stage trial of PH94B in social anxiety disorder

May 26

VistaGen names new chief commercial officer

May 04

How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

Feb 16
How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?

VistaGen Therapeutics regains Nasdaq listing compliance

Jan 06

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines

Nov 12

Financial Position Analysis

Short Term Liabilities: VTGN's short term assets ($128.1M) exceed its short term liabilities ($4.2M).

Long Term Liabilities: VTGN's short term assets ($128.1M) exceed its long term liabilities ($3.6M).


Debt to Equity History and Analysis

Debt Level: VTGN is debt free.

Reducing Debt: VTGN has no debt compared to 5 years ago when its debt to equity ratio was 1%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VTGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: VTGN has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 28.2% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.